Navigation Links
Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults
Date:3/18/2008

ctive, research-based treatments. Now we know that it's much more developmentally healthy to keep these kids in the community if at all possible and to involve their family in the re-feeding and recovery process." Physicians at the Eating Disorders Program carefully monitor the medical status of outpatients to ensure they stay medically safe while undergoing treatment.

Ongoing research has been part of the eating disorders program since its inception. In addition to a large-scale comparison of family-based and individually-oriented treatment, Lock and his colleagues are researching two types of family therapy-one focused on symptoms and weight restoration, and one on family processes. They are also conducting a recently funded study to investigate the effectiveness of a treatment called Cognitive Remediation Therapy that targets the thinking style of patients with eating disorders.

"CRT is a highly innovative approach to anorexia nervosa," said Lock. The study also includes additional treatment using cognitive and interpersonal therapy. Subjects enrolled in the study receive treatment free of charge.

Other research projects focus on brain imaging in eating-disordered patients, the management of osteoporosis in anorexia nervosa, how adolescent sufferers use Internet sites that promote eating disorders and how differences in gender and ethnicity affect eating disorder symptoms.

* For appointments or to find out more about the program's clinical

treatments, contact Suzanne Ely at (650) 498-4468.

* For research programs, contact Judy Beenhakker at (650) 723-7885.

About Lucile Packard Children's Hospital

Ranked as one of the nation's top 10 pediatric hospitals by U.S. News & World Report, Lucile Packard Children's Hospital at Stanford is a 272-bed hospital devoted to the care of children and expectant mothers. Providing pediatric and obstetric medical and surgical services and associated with the Stanford Uni
'/>"/>

SOURCE Lucile Packard Children's Hospital
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Families Play a Role in the Development of Eating Disorders
2. Scientists identify new leads for treating parasitic worm disease
3. HealthBarn(R) USA Founder Shares Secrets For Healthy Eating With Rachael Ray
4. Gene therapy could save kids from a lifetime of eating cornstarch
5. Woman from Kirksville, MO Wins $250,000 for Losing Weight and Beating Hypertension
6. New findings about the brain lead to treatment for eating disturbances
7. Breakthrough Seating Technology, ergoSEET(TM), Now Available in Indianapolis
8. Remuda Programs for Eating Disorders Launches New Anxiety Disorders Program for Teens and Children
9. MSU research indicates testosterone could guard against eating disorders
10. Effective Healthy Eating and Physical Activity Initiatives Can Reduce Health Disparities
11. Breakfast BREAKS and Teen Music Phenomenon the Jonas Brothers Team Up to Raise Awareness about the Importance of Eating Breakfast
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2